Rheumatology clinic

Antitumour necrosis factor alfa treatments for rheumatoid arthritis

Angela Fu, James Bertouch



These therapies represent an important development in the management of this common progressive inflammatory disease.

Article Extract

Rheumatoid arthritis is a common progressive inflammatory disease that can result in erosive joint damage, functional disability, and increased mortality comparable to that of triple vessel coronary artery disease and stage IV non-Hodgkins lymphoma. Epidemiological studies have shown that 30% of patients develop joint erosions within the first year and 70% within two years. Despite the early introduction of disease-modifying antirheumatic drugs (DMARDs), often in combination rather than as monotherapy, many patients continue to have active disease and to show progressive joint damage.